Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255673 | 1.00 | MAPT (0.45) | MAPTALDH1A1L3MBTL1NPSR1HTT | |
| SCHEMBL1403840 | 0.83 | PYGL (0.33) | ALDH1A1HTT | |
| SCHEMBL1403838 | 0.83 | PYGL (0.33) | ALDH1A1HTT | |
| SCHEMBL3365638 | 0.83 | PYGL (0.33) | ALDH1A1HTT | |
| SCHEMBL12156594 | 0.82 | MAPT (0.50) | MAPTALDH1A1L3MBTL1NPSR1CYP4F2 | |
| SCHEMBL17208367 | 0.74 | MAPT (0.41) | MAPTALDH1A1L3MBTL1NPSR1CYP4F2 | |
| SCHEMBL12870395 | 0.72 | MAPT (0.46) | MAPTALDH1A1L3MBTL1NPSR1CYP4F2 | |
| SCHEMBL27831272 | 0.71 | MAPT (0.57) | MAPTALDH1A1L3MBTL1NPSR1HTT | |
| SCHEMBL12870428 | 0.71 | MAPT (0.49) | MAPTALDH1A1L3MBTL1NPSR1CYP4F2 | |
| SCHEMBL1838961 | 0.70 | GRM7 (0.43) | MAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009135526-A1 | ALPHA-MERCAPTO-AMIDES | NOVARTIS AG (CH) | 2009-11-12 | — | — | WO | disclosed |
| US-6613782-B2 | For treating and/or preventing endothelin dependent conditions, e.g. cardio- and cerebro-vascular disorders such as hypertension, vasoconstriction, congestive heart failure, cerebral disorders, respiratory system disorders | NOVARTIS AG (CH) | 2003-09-02 | — | — | US | disclosed |
| US-6423727-B1 | Certain thiol inhibitors of endothelin-converting enzyme | NOVARTIS AG (CH) | 2002-07-23 | — | — | US | disclosed |
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | LOMBAERT STEPHANE DE (US) | 2002-06-27 | — | — | US | disclosed |
| CN-1297453-A | thiol endothelin converting enzyme inhibitors | NOVARTIS AG (CH) | 2001-05-30 | — | — | CN | disclosed |
| EP-1073674-A1 | THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | Novartis AG (CH) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055726-A1 | CERTAIN THIOL INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME | NOVARTIS AG (CH) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082218-A1 | Certain thiol inhibitors of endothelin-converting enzyme | ECE1, ECE2, EDNRB | MAPT 3794/4885ALDH1A1 139/4885L3MBTL1 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.